Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 9:36 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 445 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Unfractionated Heparin Clear all
Terminated Phase 3 Interventional Results available

Use of a Novel Catheter Lock Solution For Treatment of Hemodialysis Catheter Infections

NCT01483872
View directory record Official record
Conditions
Infection; Dialysis Catheter
Interventions
NAC/Tigecycline/Heparin combination lock solution, Standard anticoagulant (Heparin or Citrate)
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 70 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Sep 6, 2019 · Synced Oct 16, 2026, 9:36 PM EDT
Completed Phase 3 Interventional

Role of Coumadin in Preventing Thromboembolism in Atrial Fibrillation (AF) Patients Undergoing Catheter Ablation

NCT01006876
View directory record Official record
Conditions
Thromboembolism
Interventions
Coumadin
Drug
Lead sponsor
Texas Cardiac Arrhythmia Research Foundation
Other
Eligibility
18 Years to 75 Years
Enrollment
1,584 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 20, 2015 · Synced Oct 16, 2026, 9:36 PM EDT
Terminated Not applicable Interventional Results available

PET/CT Study in the Diagnosis of Coronary Plaque

NCT00850473
View directory record Official record
Conditions
Myocardial Infarction, Coronary Artery Disease, Cardiac Catheterization
Interventions
PET/CT
Diagnostic Test
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 29, 2018 · Synced Oct 16, 2026, 9:36 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Comparing Anti-XA Levels in Post-Cesarean Patients Undergoing Enoxaparin Thromboprophylaxis

NCT02070237
View directory record Official record
Conditions
Obesity, Obesity, Morbid, Pregnancy, Complications; Cesarean Section, Venous Thromboembolism, Postpartum Deep Phlebothrombosis, Pulmonary Embolism
Interventions
Enoxaparin
Drug
Lead sponsor
MemorialCare Health System
Other
Eligibility
18 Years and older · Female only
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated Nov 23, 2015 · Synced Oct 16, 2026, 9:36 PM EDT
Completed Phase 3 Interventional

Comparison of Angiomax Versus Heparin in Acute Coronary Syndromes (ACS)

NCT00093158
View directory record Official record
Conditions
Unstable Angina, Myocardial Infarction, Acute Disease
Interventions
Angiomax (bivalirudin) anticoagulant
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
18 Years and older
Enrollment
13,800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 21, 2007 · Synced Oct 16, 2026, 9:36 PM EDT
Completed Phase 3 Interventional Results available

Clinical Trial Comparing Two Bladder Instillations for IC/BPS

NCT03463915
View directory record Official record
Conditions
Interstitial Cystitis, Bladder Pain Syndrome
Interventions
Bladder instillation WITH triamcinolone acetonide, Bladder instillation WITHOUT triamcinolone acetonide
Drug
Lead sponsor
Olivia Cardenas-Trowers, M.D.
Other
Eligibility
18 Years and older · Female only
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Sep 1, 2021 · Synced Oct 16, 2026, 9:36 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Heparin Versus Normal Saline in Peripherally Inserted Central Catheter Lines

NCT05029596
View directory record Official record
Conditions
Cancer
Interventions
Normal Saline Group, Heparin Group
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
142 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 16, 2026, 9:36 PM EDT
Completed Not applicable Interventional Results available

Study Comparing Synthetic Vascular Grafts in Patients With Peripheral Artery Disease (PAD) Who Require Artery Bypass.

NCT01113892
View directory record Official record
Conditions
Peripheral Arterial Occlusive Disease
Interventions
vascular grafts
Device
Lead sponsor
Maquet Cardiovascular
Industry
Eligibility
21 Years and older
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
18
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Palo Alto, California + 11 more
Source: ClinicalTrials.gov public record
Updated May 22, 2020 · Synced Oct 16, 2026, 9:36 PM EDT
Terminated Phase 2 Interventional Results available

HEROIC (Heparin Requirement in Counterpulsation)

NCT00445211
View directory record Official record
Conditions
Cardiogenic Shock
Interventions
Heparin, Without Heparin
Drug · Other
Lead sponsor
Corewell Health East
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated May 19, 2017 · Synced Oct 16, 2026, 9:36 PM EDT
Terminated Phase 3 Interventional Results available

ENDOvascular Interventions With AngioMAX: The ENDOMAX Trial

NCT01913483
View directory record Official record
Conditions
Peripheral Endovascular Interventions, Bleeding
Interventions
Bivalirudin, Unfractionated Heparin
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
18 Years and older
Enrollment
732 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
39
States / cities
Hot Springs, Arkansas • Stanford, California • Clearwater, Florida + 31 more
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 16, 2026, 9:36 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Healthy Volunteer PK/PD, Safety and Tolerability Study of Second Generation Andexanet Alfa

NCT03083704
View directory record Official record
Conditions
Bleeding
Interventions
Andexanet alfa (Gen 1 Process 2), Apixaban 5 MG, Rivaroxaban 20 MG, Enoxaparin sodium, Edoxaban 60 MG, Andexanet alfa (Gen 2), Andexanet alfa (Gen 1 Process 3), Apixaban 10 MG, Rivaroxaban 10 MG
Biological · Drug
Lead sponsor
Portola Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
153 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Aug 8, 2023 · Synced Oct 16, 2026, 9:36 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Phase 2 Healthy Volunteer Study to Evaluate the Ability of PRT064445 to Reverse the Effects of Several Blood Thinner Drugs on Laboratory Tests (Module 3 of 4)

NCT03551730
View directory record Official record
Conditions
Healthy Volunteers
Interventions
PRT064445/Enoxaparin, Placebo/Enoxaparin, Placebo
Combination Product · Drug
Lead sponsor
Portola Pharmaceuticals
Industry
Eligibility
18 Years to 45 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 22, 2023 · Synced Oct 16, 2026, 9:36 PM EDT
Terminated Phase 4 Interventional Results available

Maintaining Patency in BioFlo Implanted Port Catheters With Saline Only Flushes

NCT02923830
View directory record Official record
Conditions
Obstruction; Catheter, Infusion Catheter (Vascular), Catheter; Complications (Indwelling Catheter)
Interventions
Heparinized saline catheter flush, Saline-only catheter flush
Other · Drug
Lead sponsor
TriHealth Inc.
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
6
States / cities
Cincinnati, Ohio • Hamilton, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 11, 2019 · Synced Oct 16, 2026, 9:36 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Apixaban for the Treatment of Deep Vein Thrombosis or Pulmonary Embolism

NCT00643201
View directory record Official record
Conditions
Venous Thrombosis
Interventions
Enoxaparin, warfarin, Placebo for apixaban, Placebo for enoxaparin, Placebo for warfarin, apixaban
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
5,614 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
73
States / cities
Birmingham, Alabama • Mobile, Alabama • Fort Smith, Arkansas + 68 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2014 · Synced Oct 16, 2026, 9:36 PM EDT
Completed No phase listed Observational

Biorepository of Biospecimen Samples in Matched Healthy Control Participants and Participants Diagnosed With Diabetic Kidney Disease, Chronic Kidney Disease, or Type 2 Diabetes

NCT05631119
View directory record Official record
Conditions
Diabetic Kidney Disease, Diabetes Type 2, Chronic Kidney Diseases, Healthy
Interventions
Not listed
Lead sponsor
Sanguine Biosciences
Industry
Eligibility
18 Years to 85 Years
Enrollment
40 participants
Timeline
2022 – 2023
U.S. locations
1
States / cities
Woburn, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 3, 2023 · Synced Oct 16, 2026, 9:36 PM EDT
Completed Phase 3 Interventional Results available

Edoxaban for Prevention of Blood Vessels Being Blocked by Clots (Thrombotic Events) in Children at Risk Because of Cardiac Disease

NCT03395639
View directory record Official record
Conditions
Cardiac Disease
Interventions
Edoxaban, Standard of Care (SOC)
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
1 Day to 17 Years
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
14
States / cities
Birmingham, Alabama • Mesa, Arizona • Los Angeles, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2022 · Synced Oct 16, 2026, 9:36 PM EDT
Completed Phase 2 Interventional Results available

Study Of Weight-Based Versus Standard Dose Enoxaparin Thromboprophylaxis In High-Risk Hospitalized Cancer Patients

NCT02706249
View directory record Official record
Conditions
Venous Thormboembolism
Interventions
Enoxaparin
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
2
States / cities
Boston, Massachusetts • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 8, 2021 · Synced Oct 16, 2026, 9:36 PM EDT
Terminated Phase 1 Interventional

Pilot/Ph I Safety and Efficacy of ODSH in Protein Losing Enteropathy Secondary to Single Ventricle Palliative Surgery

NCT01161641
View directory record Official record
Conditions
Protein Losing Enteropathy
Interventions
ODSH at 0.125 mg/kg/h, ODSH at 0.375 mg/kg/h, ODSH at 0.250 mg/kg/h
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
6 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
4
States / cities
Los Angeles, California • Boston, Massachusetts • Ann Arbor, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2021 · Synced Oct 16, 2026, 9:36 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effect of Increased Free Fatty Acids on Leptin Function

NCT01520454
View directory record Official record
Conditions
Obesity, Leptin Resistance
Interventions
Saline, Intralipid, Water, oral fat, Heparin
Drug · Dietary Supplement
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 11, 2018 · Synced Oct 16, 2026, 9:36 PM EDT
Completed No phase listed Observational

Reference Range for abioSCOPE® Device With the PSP Assay in a Generally Healthy Adult Population

NCT04409561
View directory record Official record
Conditions
Sepsis, Septic Shock, Healthy
Interventions
Blood collection
Device
Lead sponsor
Abionic SA
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Timeline
2021 – 2022
U.S. locations
1
States / cities
Toledo, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 2, 2022 · Synced Oct 16, 2026, 9:36 PM EDT
Active, not recruiting Not applicable Interventional

Blood Purification for the Treatment of Pathogen Associated Shock

NCT05011656
View directory record Official record
Conditions
Septic Shock
Interventions
Seraph-100 + State of the Art Care, State of the Art Care
Device
Lead sponsor
ExThera Medical Corporation
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
9
States / cities
Washington D.C., District of Columbia • Brunswick, Georgia • Ann Arbor, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Oct 16, 2026, 9:36 PM EDT
Completed No phase listed Observational

Anticoagulation Strategies for Acute Venous Thromboembolism in Patients With End-Stage Renal Disease Using USRDS Data

NCT04818151
View directory record Official record
Conditions
Venous Thromboembolic Disease, Kidney Failure, Chronic
Interventions
Warfarin, Apixaban
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
14,914 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 26, 2021 · Synced Oct 16, 2026, 9:36 PM EDT
Completed Phase 2 Interventional

Carotid With Bivalirudin Angioplasty

NCT00812383
View directory record Official record
Conditions
Carotid Artery Disease
Interventions
RX ACCULINK™ Carotid Stent System; RX ACCUNET™ Embolic Protection System; PercuSurge GuardWire® 3-6 Temporary Occlusion and Aspiration System
Device
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
18 Years and older
Enrollment
299 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2019
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Oct 28, 2020 · Synced Oct 16, 2026, 9:36 PM EDT
Recruiting Phase 2 Interventional

Using Placental Pathology to Prevent Recurrent Adverse Pregnancy Outcomes: A Pilot Project

NCT06004674
View directory record Official record
Conditions
Adverse Pregnancy Outcome
Interventions
Lovenox 40mg
Drug
Lead sponsor
Endeavor Health
Other
Eligibility
18 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Oct 16, 2026, 9:36 PM EDT